Medtronic Australasia Pty Ltd.
97 Waterloo Road North Ryde, NSW 2113
Phone: 1800 777 808

MiniMed® 640G System^

Many factors can affect your glucose levels, such as diet, exercise and stress levels and you may need a system that can give you better control: a system that thinks**. The MiniMed® 640G System^ features innovative technology to more closely mimic the way a healthy pancreas delivers basal insulin to the body in order to help you to achieve better control.

Our MiniMed® 640G System^ combines four elements to give you:

 

The MiniMed® 640G System^ can guide you towards better control¹ by providing advanced protection from hypoglycaemic episodes² and offering greater convenience for easier daily management of your diabetes.

Medtronic 640G Insulin Pump

Like to find out more about the MiniMed Veo Insulin Pump?

Request a Call

Medtronic Smart Guard

It Thinks

The MiniMed® 640G insulin pump with SmartGuard™ closely mimics the way a healthy pancreas delivers basal insulin to your body. As part of the MiniMed® system it can guide you towards better control1 by providing advanced protection from hypo events2. All of this with personalised settings to fit your daily life and therapy needs. Learn more.

Mio Set

Infusion sets to suit you

Our infusion sets with the innovative MiniMed® connection are designed to provide a more secure insulin delivery from your pump to your body. The infusion sets come in a diverse range of colours and styles to meet your lifestyle needs, allowing you to be more comfortable and confident! Learn more.

Medtronic Bayer Contour Meter

3-in-1 Blood Glucose Meter for added convenience

The Bayer CONTOUR® NEXT LINK 2.4 is the only available blood glucose meter shown to accurately send glucose readings wirelessly to your MiniMed® 640G saving you time and effort. It also allows you to discreetly send a bolus directly to your pump and to conveniently download blood glucose and insulin information to CareLink®. Learn more.

CGM

Advanced sensors for better control

Continuous Glucose Monitoring (CGM) technology tracks glucose levels in your body 24 hours a day. CGM uses a sensor that connects to your MiniMed® insulin pump giving you early warnings of highs and lows. Results show that CGM can lower HbA1c levels1 and reduce the time of hypos3, and aims to improve quality of life. Learn more.

Carelink

Therapy tracking for better control

CareLink® Personal Software is a convenient online tool that accurately tracks your insulin usage and glucose levels, allowing you to compare any changes in glucose levels with your daily activities, such as meals and exercise routines. Clear charts and graphs show you these changes and help you and your healthcare provider discover patterns and adjust your therapy for better control. Learn more.

References:

3. Based on the recommendation insulin pump infusion set change once every 2-3 days compared to 4 injections a day for 30 days.
4. Hermanides J. et al. Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled type 1 diabetes; a randomized controlled trial. Diabetic Medicine. 2011;28(10):1158-67.
5.Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. NEJM. 2010, Jul 22;363(4):311-20
6.Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Sustained Benefits of Continuous Glucose Monitoring through 12 Months of Sensor Use in the JDRF CGM Randomized Clinical Trial. ADA 2009 p. 204-OR.
7. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Sustained Benefits of Continuous Glucose Monitoring on HbA1c, Glucose Profiles, and Hypoglycemia in Adults with Type 1 Diabetes. Diabetes Care. 2009, (32): 2047-2049.
8. Raccah D, Sulmont V, Reznik Y et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the Real Trend study. Diabetes Care. 2009, December; 32(12):2245-50.
9. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. 2008, October 2;359(14):1464-76.
10. Deiss D, Bolinder J, Riveline JP et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006, December; 29(12):2730-2.
11. O’Connell MA, Donath S, O’Neal DN et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomized controlled trial. Diabetologia. 2009, April 25.
12. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-Based InsulinPump Interruption for Reduction of Hypoglycemia. NEJM. 2013 June 22. Published ahead of print.
13. Ly TT, et al. Reduction of Severe Hypoglycemia with Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension in Patients with Type 1 Diabetes. Abstract and Oral (228-OR) presented at 73rd Scientific Sessions, American Diabetes Association. June 21-25, 2013. Chicago, IL.